IL5 and asthma: Tozorakimab reduced biomarkers of inflammation, including serum IL-5, IL-13 and blood eosinophils, in a phase 1 study [178] and is being evaluated in a phase 2 study in patients with asthma (ClinicalTrials.gov: NCT04570657).